Yahoo Finance: Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile?
Agios Pharmaceuticals is heading into its March 2026 quarter earnings after analysts recently revised their loss-per-share estimates higher while still anticipating a loss, with revenue projected to ...
Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile?
Invezz: Why is Sun Pharma betting $11.75B on a struggling US drugmaker?
Sun Pharma to buy Organon in $11.75 billion all-cash deal at $14 per share. Deal boosts presence in women’s health, biosimilars and innovative drugs. Transaction awaits approvals, with closing ...
--(BUSINESS WIRE)--Iris Pharma is a world-leading Contract Research Organization (CRO) offering preclinical and clinical ophthalmology research services. Iris Pharma works hand-in-hand with customers ...
Forbes: From Pills To Devices: How Pharma Is Expanding Into The Medical Device Market
In recent years, pharmaceutical companies have broadened their horizons, moving beyond drug development to enter the medical device market. This strategic shift allows pharma to offer integrated ...
From Pills To Devices: How Pharma Is Expanding Into The Medical Device Market
FiercePharma: Amid high-profile injectable launch, Novo Nordisk scores with its pill version of obesity drug Wegovy
Benzinga.com: CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive ...
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
Business Wire: Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium